Amundi Asset Management US’s Fate Therapeutics FATE Stock Holding History

Amundi Asset Management US’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$37.7M	Buy	456,699 +22,613	+5%	+$2.17M	0.03%	497
2020 Q4	$39.5M	Buy	434,086 +301,687	+228%	+$18.7M	0.03%	457
2020 Q3	$5.29M	Buy	132,399 +124,799	+1,642%	+$4.36M	0.01%	882
2020 Q2	$261K	Sell	7,600 -100	-1%	-$2.98K	﹤0.01%	1343
2020 Q1	$171K	Buy	+7,700	New	+$195K	﹤0.01%	1357
2019 Q3	–	Sell	-34,439	Closed	-$699K	–	1649
2019 Q2	$699K	Sell	34,439 -8,504	-20%	-$153K	﹤0.01%	1315
2019 Q1	$755K	Sell	42,943 -7,290	-15%	-$115K	﹤0.01%	1257
2018 Q4	$645	Sell	50,233 -1,666	-3%	-$23.2K	﹤0.01%	1230
2018 Q3	$845K	Buy	+51,899	New	+$614K	﹤0.01%	1287

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's FATE Position: Q1 2021 in Review

Amundi Asset Management US increased its Fate Therapeutics (FATE) stake by 5.2% in Q1 2021, buying an estimated $2.17M and bringing the position to 456,699 shares worth $37.7M. The position accounts for 0.03% of the portfolio, ranked #497.

Amundi Asset Management US first reported a position in FATE in Q3 2018 and has held it in 9 quarters since. The position peaked at $39.5M in Q4 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

Amundi Asset Management US held 456,699 shares of Fate Therapeutics worth $37.7M as of Q1 2021.
Amundi Asset Management US bought 22,613 Fate Therapeutics shares in Q1 2021, an estimated $2.17M.
Fate Therapeutics made up 0.03% of Amundi Asset Management US's portfolio in Q1 2021, its #497 holding.
Amundi Asset Management US first reported a position in Fate Therapeutics in Q3 2018 and has held it in 9 quarters since.
Amundi Asset Management US's Fate Therapeutics position peaked at $39.5M in Q4 2020.
260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.